UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 294

Sortiert nach

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Clinical cancer research, 2016-01, Vol.22 (1), p.44-53

2016

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1415-1421

2013

Link zum Volltext

Verfügbarkeit prüfen

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Journal of clinical oncology, 2008-05, Vol.26 (15), p.2442-2448

2008

Link zum Volltext

Verfügbarkeit prüfen

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-11, Vol.28 (33), p.4953-4960

2010

Link zum Volltext

Verfügbarkeit prüfen

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3794-3801

2009

Link zum Volltext

Verfügbarkeit prüfen

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Cancer medicine (Malden, MA), 2023-04, Vol.12 (8), p.9384-9391

2023

Link zum Volltext

Verfügbarkeit prüfen

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes

The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1632-1639

2008

Link zum Volltext

Verfügbarkeit prüfen

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4104-4111

2022

Link zum Volltext

Verfügbarkeit prüfen

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

BMC cancer, 2019-01, Vol.19 (1), p.70-9, Article 70

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.162-168

2021

Link zum Volltext

Verfügbarkeit prüfen

Salivary Gland Malignancies

Hematology/oncology clinics of North America, 2015-12, Vol.29 (6), p.1145-1157

2015

Link zum Volltext

Verfügbarkeit prüfen

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-01, Vol.14 (1), p.124-129

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

BMC cancer, 2012-10, Vol.12 (1), p.449-449, Article 449

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Clinical cancer research, 2010-11, Vol.16 (21), p.5260-5268

2010

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Advances in radiation oncology, 2022-03, Vol.7 (2), p.100857-100857, Article 100857

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

International journal of radiation oncology, biology, physics, 2010-11, Vol.78 (3), p.696-702

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Clinical cancer research, 2017-05, Vol.23 (10), p.2442-2450

2017

Link zum Volltext

Verfügbarkeit prüfen

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

Clinical cancer research, 2007-08, Vol.13 (15), p.4632s-4636s

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Clinical cancer research, 2008-10, Vol.14 (19), p.6324-6329

2008

Link zum Volltext

Verfügbarkeit prüfen

Value‐Based Care in Lung Cancer

The oncologist (Dayton, Ohio), 2016-08, Vol.21 (8), p.903-906

2016

Link zum Volltext

Verfügbarkeit prüfen

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

Head & neck, 2023-02, Vol.45 (2), p.391-397

2023

Link zum Volltext

Verfügbarkeit prüfen

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.e97-e99

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(265)
Mit Volltextzugriff
(259)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(205)
Life Sciences & Biomedicine
(161)
Humans
(123)
Female
(71)
Male
(64)
Oncology
(48)
Middle Aged
(35)
Adult
(34)
Biological And Medical Sciences
(32)
Aged
(31)
Medical Sciences
(31)
Physical Sciences
(23)
Treatment Outcome
(23)
Technology
(22)
Chemotherapy
(21)
Lung Neoplasms - Drug Therapy
(21)
Animals
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Risk Factors
(18)
Neoplasm Staging
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Salivary Gland Malignancies

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Value‐Based Care in Lung Cancer

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Suchergebnisse filtern